Additional file 1 of Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Wientjes, Maike H. M.; Atiqi, Sadaf; Wolbink, Gerrit Jan; Nurmohamed, Michael T.; Boers, Maarten; Rispens, Theo; de Vries, Annick; van Vollenhoven, Ronald F.; van den Bemt, Bart J. F.; den Broeder, Alfons A.

doi:10.6084/m9.figshare.14812440.v1

13063_2021_5358_MOESM1_ESM.docx (58.29 kB)

Additional file 1 of Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

journal contribution

posted on 2021-06-20, 03:48 authored by Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Annick de Vries, Ronald F. van Vollenhoven, Bart J. F. van den Bemt, Alfons A. den Broeder

Additional file 1. SPIRIT 2013 Checklist.

Funding

ZonMw

History

Usage metrics

Keywords

Rheumatoid arthritis Adalimumab Anti-TNF Therapeutic drug monitoring Drug concentration Switching Test-treatment trial Design

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

Funding

ZonMw

History

Usage metrics

Categories

Keywords

Licence

Exports